CAR T-Cell Therapy for the Management of Multiple Myeloma

Dr Madduri discusses triple-class exposed relapsed and refractory multiple myeloma.

Drs Deepu Madduri and Parameswaran Hari explain the high rates of use of healthcare resources in relapsed/refractory multiple myeloma and recommend strategies that may reduce resource utilization and treatment variability.

Current treatment challenges in relapsed/refractory multiple myeloma, as highlighted by healthcare professionals, and the rationale for exploring CAR T-cell therapy as a newer treatment modality.

Drs Deepu Madduri and David S. Siegel comment on what has been learned more recently about the biology and manifestation of relapsed/refractory multiple myeloma and remark on how this has impacted drug development.

Parameswaran Hari, MD, MRCP, of the Medical College of Wisconsin, comments on the rationale for studying CAR T-cell therapy as a treatment option for relapsed/refractory multiple myeloma and the discusses the role of more recent data in supporting cost and coverage decisions by payers.

Considerations for where CAR T-cell therapy may fit into the standard of care for relapsed/refractory multiple myeloma and insight regarding patient selection for the newer treatment modality.

An overview of the most recent clinical trial data available for the use of CAR T-cell therapy in relapsed/refractory multiple myeloma, as presented on at the 2020 ASH annual meeting.

Hematology/oncology experts explain why early referral to an academic center is important when approaching a case of relapsed/refractory multiple myeloma, especially as CAR T-cell therapy becomes a viable option for certain patients.

Considerations for assessing the long-term value of CAR T-cell therapies available to treat relapsed/refractory multiple myeloma.

Implications for using real-world data to better understand how to use CAR T-cell therapy as treatment for relapsed/refractory multiple myeloma and suggestions on what needs to be analyzed further.

Typical adverse events associated with the use of CAR T-cell therapy for relapsed/refractory multiple myeloma and recommendations for managing patients during and after treatment.

Drs Deepu Madduri, Parameswaran Hari, and David S. Siegel discuss the types of data that factor into their treatment decisions for patients with relapsed/refractory multiple myeloma.